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Bone defects and improper healing of fractures are an increasing public health burden,
and there is an unmet clinical need in their successful repair. Gene therapy has been
proposed as a possible approach to improve or augment bone healing with the potential
to provide true functional regeneration. While large numbers of studies have been
performed in vitro or in vivo in small animal models that support the use of gene
therapy for bone repair, these systems do not recapitulate several key features of a
critical or complex fracture environment. Larger animal models are therefore a key
step on the path to clinical translation of the technology. Herein, the current state of
orthopedic gene therapy research in preclinical large animal models was investigated
based on performed large animal studies. A summary and an outlook regarding
current clinical studies in this sector are provided. It was found that the results found
in the current research literature were generally positive but highly methodologically
inconsistent, rendering a comparison difficult. Additionally, factors vital for translation
have not been thoroughly addressed in these model systems, and the risk of bias was
high in all reviewed publications. These limitations directly impact clinical translation of
gene therapeutic approaches due to lack of comparability, inability to demonstrate non-
inferiority or equivalence compared with current clinical standards, and lack of safety
data. This review therefore aims to provide a current overview of ongoing preclinical
and clinical work, potential bottlenecks in preclinical studies and for translation, and
recommendations to overcome these to enable future deployment of this promising
technology to the clinical setting.
Keywords: bone regeneration, gene therapy, preclinical models, translational medical research, orthopedic and
trauma, regenerative medicine
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INTRODUCTION
While bone is highly competent at regeneration (Hadjidakis and
Androulakis, 2006), a variety of situations can lead to damage that
cannot be fully repaired by endogenous mechanisms. One of the
most challenging examples is a major traumatic event resulting
in significant bone loss, fragmentation, substantial damage to
the surrounding soft tissue, or some combination of the above.
Alternatively, other common etiologies for impaired healing and
indications for augmentation of bone regeneration are surgical
resection of a tumor or osteomyelitis (chronic bone infection),
spinal fusion, and alveolar ridge atrophy caused by edentulism.
Large bone defects that cannot be repaired by endogenous
mechanisms leaving a permanent gap in the bone are termed
“critical defects” (see Figure 1). Exactly how critical defects are
defined is controversial, though sometimes a ratio of defect size to
bone length is used. Typically, in humans, a defect of >1–2 cm in
length where 50% of the bone circumference is lost will be critical
(Lindsey et al., 2006; Spicer et al., 2012; Schemitsch, 2017). It is
important to note that defect site and other factors have a major
influence and may lead to defects that do not fit these parameters
becoming critical or those that do fit them healing fully (Sanders
et al., 2014; Schemitsch, 2017).
Complications in small fracture healing are commonly seen in
older patients or those suffering with comorbidities, for example,
disorders associated with systemic inflammation such as diabetes
(Claes et al., 1999, 2012). This is typically manifested as delayed
union, while cessation of fracture repair without full defect
closure is often termed a “non-union” (Panagiotis, 2005; Tall,
2018). Non-unions are typically filled with fibrotic tissue and have
some superficial similarities to a joint (see Figure 1), leading to
the alternative name of pseudoarthrosis. With the increasing age
of the general population and prevalence of chronic conditions
(Anderson and Horvath, 2004; van Oostrom et al., 2016), the
clinical burden of impaired fracture healing is likely to increase
in the future. Consequently, there has been a great deal of interest
in the use of regenerative medicine and tissue engineering to
encourage impaired bone repair. Numerous combinations of
genes, vectors, proteins, cells, scaffolds, and methods to apply
them have been proposed or investigated (Grol and Lee, 2018).
When considering orthopedic bone repair, gene therapy
has several advantages over competing methods. The present
standard of regenerative, intraoperative care for such defects is
a bone autograft. Bone is removed from a healthy donor site
on the patient (typically the iliac crest or fibula) and then used
to fill the original defect (see Figure 1) or space prefabricated
with the Masquelet technique. While this approach now has
a high success rate, it is a complex surgical procedure with
a risk of donor site morbidity (Kuik et al., 2016). Alternative
approaches include synthetic bone substitutes and allo- or
xenografts; however, these are limited in osteoinductive potential
(Buser et al., 2016; Wang and Yeung, 2017; Haugen et al.,
2019; Sohn and Oh, 2019). Recombinant growth factors to
encourage endogenous repair have seen use in the clinic; however,
their effectiveness is impacted by short biological half-life,
immunogenicity in some patients, and a host of other side
effects (Talwar et al., 2001; Hwang et al., 2009). To ensure a
physiologically relevant level of protein is present long enough to
induce an effect of a supraphysiological initial dose (which may
have adverse effects) (Aspenberg, 2013; James et al., 2016), repeat
applications (clinically challenging), or a sustained release system
(technically challenging) is required. Some attempts have been
made to develop small molecules to encourage bone regeneration;
however, these approaches face similar problems to those of
growth factors (Paralkar et al., 2003; Laurencin et al., 2014). Gene
therapy can potentially avoid all of these issues by delivering
genetic blueprints. A single treatment or application gene therapy
can lead to targeted, sustained, and controlled expression of
therapeutic gene/s of interest, all of which can be tuned using
vector and expression cassette design.
Various gene therapy approaches are now available and
intensely studied for clinical translation. An important part of
any gene therapy is the vector or method by which genes of
interest are introduced to the target cells. Traditionally, a host
of different viruses have been used for this purpose, making
use of their natural adaptions for cell targeting and entry to
deliver genetic information (Lundstrom, 2018). However, viral
vectors can be cytotoxic (Büning and Schmidt, 2015) and have
the potential to induce an immune response, possibly rendering
the initial therapy or follow-up treatments ineffective (Nayak and
Herzog, 2010). Furthermore, certain vectors encourage transgene
integration in the host genome leading to potentially dangerous
insertional mutagenesis effects (Knight et al., 2013; David and
Doherty, 2017). Because of this, there is an increasing push
toward non-viral gene therapies as a safer and therefore more
easily translatable alternative in situations where only short-
term transgene expression is required. In such methods, nucleic
acids are introduced either “naked” or as part of a synthetic
carrier such as a capsule or nanoparticle (Yin et al., 2014). While
these methods are deemed to be often safer, the advantageous
aspects of viral gene delivery are lost. Non-viral approaches
typically show low efficiency and limited transgene persistence,
and the host immune responses to both the carrier and its nucleic
acid contents are still a concern in terms of safety and efficacy
(Al-Dosari and Gao, 2009). A possible approach to mitigate
the problems of both approaches is ex vivo gene therapy, a
combination of cell and gene therapy (CGT). In such approaches,
cells are removed from the patient or donor, transduced or
transfected in the lab, screened for successful modification, and
then reintroduced to the patient (Gregory-Evans et al., 2012) (see
Figure 2). Such approaches are theoretically attractive and have
already seen some success in humans in a variety of conditions
(Kumar et al., 2016; Hirsch et al., 2017). However, they are
expensive, time-consuming, and labor-intensive and introduce a
host of new safety and regulatory issues. These limitations act as
a major barrier to widespread clinical translation.
Another vital consideration is the therapeutic gene to be
delivered. Many potential options have been proposed to
encourage bone repair. Perhaps the most commonly used
options to date are members of the bone morphogenetic protein
(BMP) family of growth factors, due to their vital role in bone
development, homeostasis, and repair (Bragdon et al., 2011;
Wang et al., 2014). A popular alternative is vascular endothelial
growth factor (VEGF) to encourage angiogenesis, vital in such
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FIGURE 1 | A male patient 29 years of age sustained a left tibial open fracture. (A) Initial anterior–posterior (AP). (B) Lateral radiographs of left tibia showing the
midshaft fracture. (C) AP. (D) Lateral tibial radiographs showing that the fracture was stabilized with an intramedullary nail (note the tibial small defect laterally).
(E) Lateral tibial radiograph at 4 months demonstrating lack of healing activity. (F) Intraoperative picture at 6 months showing non-union/bone loss and visualization
of the nail. (G) Intraoperative picture showing bone grafting of the tibia with autologous bone graft. (H) AP postoperative. (I) Closer AP postoperative radiograph
showing the area of small bone defect filled with the autologous bone graft. (J) AP radiograph 3 months lateral showing osseous healing of the tibial small defect.
a highly vascularized tissue as bone. These and numerous other
options have been reviewed extensively elsewhere (Betz et al.,
2018; Grol and Lee, 2018; Shapiro et al., 2018).
Each combination of delivery method, target cell population,
and vector has a unique combination of positives and negatives,
but common issues include targeting the correct cell population
and establishing a suitable dose (Waehler et al., 2007; Yin
et al., 2014). New approaches to vector and expression cassette
design have been attempted to address these problems, but
novel delivery methods may also be able to contribute to
technological advancement and translatability. Scaffold or gene-
activated matrix (GAM)-based delivery has drawn a great deal of
interest from the tissue engineering community. In this approach,
the gene therapy is immobilized on a 3D tissue engineering
scaffold, allowing precise localization of the gene therapy to site of
interest (Raisin et al., 2016; D’Mello et al., 2017). This technology
has been developed further with the use of microbubble carriers,
which can be sheared using ultrasound, providing unprecedented
spatiotemporal control of gene delivery (Zhou et al., 2008;
Nomikou et al., 2018). However, such approaches are still in their
infancy and require further development.
Research and development of regenerative approaches for
bone repair does not differ in terms of its iterative preclinical
approach from other biomedical research fields; in fact, the large
majority of preclinical animal research has been performed in
small rodent models. While small rodent models have many
advantages, they often fail to recapitulate key aspects of human
biology (Chong et al., 2013; Seok et al., 2013; von Scheidt et al.,
2017; King, 2018). Consequently, they can be poor predictors of
the behavior of a treatment or therapy in humans. In the case of
bone repair, the sheer difference in size, biomechanical loading,
and biomechanics is particularly important, but mechanisms and
rates of bone remodeling and biomechanics also vary widely
between species (Reichert et al., 2009; Wancket, 2015; McGovern
et al., 2018). Larger animal models are more similar to humans
with regard to many of these factors, having the potential to
be better models for orthopedic treatments. Rabbits (Inui et al.,
1998; Murakami et al., 2002), sheep (Kirker-Head et al., 1998;
den Boer et al., 2003), goats (Xu et al., 2005; Lian et al., 2009),
dogs (Cook et al., 1994; Sumner et al., 2003), pigs (Lin et al., 2015;
Bez et al., 2017), horses (Backstrom et al., 2004; Ishihara et al.,
2008), and non-human primates (Andersson et al., 1978; Cook
et al., 2002) have all been used as animal models for orthopedic
implants or regenerative approaches to bone repair. Porcine bone
has similar morphology and microstructure to that of humans;
however, pigs are large and difficult to handle (Reichert et al.,
2009; Wancket, 2015; Perleberg et al., 2018). Dogs also possess
relevant bone physiology in several regards, but their status as a
companion animal has prompted public concern over their use
(O’Loughlin et al., 2008; McGovern et al., 2018). Sheep display
favorable bone qualities, relative ease of handling, and lack of
public objection to their use in research (Malhotra et al., 2014)
but are still more expensive and difficult to house than are
small rodents. There is no animal model that is unambiguously
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FIGURE 2 | A summary of possible approaches to gene therapy for bone regeneration (kindly provided by D. Ilas). P, promoter; TG, transgene.
superior for bone research, and practical considerations such as
animal handling, housing, and cost, which typically favor smaller
models, cannot be ignored.
While preclinical animal experiments are required for the
large majority of new drugs and treatments developed in
Europe and the United States (Agency, 2008), regulators are
currently highly flexible with regard to species choice. Industry
guidelines published by the United States Food and Drug
Administration (FDA) state that the species should demonstrate
a biological response similar to that of humans and that the
comparability of physiology and anatomy to humans should
play a role (Center for Biologics Evaluation and Research,
2013). The European Medicines Agency (EMA) provides similar
guidelines. It remains for the investigator to demonstrate that
their species of choice is appropriate with regard to these
and several additional factors (Agency, 2015). Testing in a
second species is encouraged but sometimes not required,
and there is no requirement to use larger animal models




The PICO (Problem, Intervention, Comparison, and Outcome)
question that the review attempts to answer is as follows:
Has gene therapy been successfully applied to regenerate
bone in large animal models? We also aimed to assess
the various methodologies and approaches used across the
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TABLE 1 | A simplified biomedical technology readiness level (TRL) framework, based on the United States government DoD TRA Deskbook (Office of the director of
defense and engineering, 2009).



























field, making a thorough survey of methods that have been
employed in large animal models. Finally, we assessed the
risk of bias (RoB) of all of the publications using an
established framework.
The information gathered to answer these questions was
then used to conduct a technology readiness assessment
(TRA). A TRA aims to estimate the technology readiness
level (TRL) of a technology, in this case gene therapy for
orthopedic bone regeneration. TRAs were first developed by
the National Aeronautics and Space Administration (NASA)
to allow consistent discussion of technical maturity across
various technologies but have now become a popular assessment
technique in many diverse fields. Simply, TRAs rank a technology
on a 9- or 10-point scale of TRLs, with higher values indicating
technological maturity. In bioscience/medicine, these scores
correspond to closeness to clinical translation. TRAs are still
uncommon in the fields of biomedicine and biotechnology,
and consequently, there is no widely accepted framework for
their use. In this case, a slightly modified version of the
United States Department of Defense TRA Deskbook guidelines
for biomedical TRLs (Office of the Director of Defense Research
and Engineering, 2009) has been applied, a highly simplified
version of which can be seen in Table 1. More detailed versions
of the frameworks for biologics and medical devices are provided
in Supplementary Table 4.
Search Strategy
The databases MEDLINE, EMBASE, and BIOSIS were searched
in August 2019 for terms relating to animal models, gene
therapy, and bone. Controlled or curated vocabulary was used
for all databases, with an additional topic search added to the
BIOSIS search due to a lack of sufficiently specific curated terms.
The initial search returned 1,483 publications, which were then
taken for filtering (see Figure 3).
See the Supplementary Information for a detailed description
of the literature search.
Filtering Strategy
References were exported from the databases into the reference
management software EndNote X7. EndNote’s duplicate
detection function and a manual search were used to filter for
duplicates. A relevance search was then conducted based on the
listed inclusion and exclusion criteria.
Inclusion criteria were as follows:
• Use of gene therapy,
• Focus on bone repair,
FIGURE 3 | Overview of the preclinical literature search and filtering process.
• Use of large animal models, and
• English language.
Exclusion criteria were as follows:
• Exclusive use of small animal models (rabbits and smaller);
• Exclusively in vitro; and
• Review articles, letters to the editor, and other non-research
article types.
A first pass was made by searching the titles for terms
associated with exclusion criteria (e.g., “mouse”). Identified
titles were manually examined and excluded if a reasonable
assumption that exclusion criteria were met could be made
(e.g., the publication “Combination therapy with BMP-2 and a
systemic RANKL inhibitor enhances bone healing in a mouse
critical-sized femoral defect” was excluded at this stage, as there
was no indication that a large animal model was used). The
remaining publications were manually screened, with both the
titles and abstracts consulted. Finally, an availability check was
conducted. See Figure 3 for a summary of the search and
filtering process.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 5 March 2021 | Volume 9 | Article 626315
fbioe-09-626315 March 17, 2021 Time: 13:47 # 6
Wilkinson et al. Preclinical Technology Readiness of Orthopedic Gene Therapy
Automated Machine Reading and
Visualizations
In order to provide a summary overview of the most
common and recurring topics shared by the selected systematic
review publications, we have developed a Python script, which
automatically creates a visual representation of the most common
key phrases, involved authors, journals, and publication years.
We provide and maintain the current version as Jupyter
Notebook under the following GitHub Repository: https://github.
com/intonumbers/pubmed-insights.
First, we have queried the Entrez query and database system
at the National Center for Biotechnology Information (NCBI)
via their Entrez Programming Utilities (E-utilities) API for the
corresponding 33 selected publications (Sayers, 2009).
To extract the most frequent key terms, we have included the






Our data munging process’s first step was to remove all
punctuation marks, special characters, and figures for each of
the mentioned key–value pairs and replace all capital letters with
their corresponding lowercase letters. We then removed common
stop words (detailed stop-words list see GitHub repository) and
lemmatized the remaining words using NLTK WordNet’s1 built-
in Morphy function. Next, we have formed all n-grams between
word-size 2 and 5 for all key–value pairs per publication dataset
except for the keywords key–value pair, where we have defined
each entry as n-gram regardless of their size.
Afterward, we have removed all n-gram duplicates per
publication dataset.
For the final word cloud visualization, we have implemented
a weighting score by multiplying the number of publications
in which the n-gram occurs by the size of the corresponding
n-gram and manually removed less meaningful n-grams (detailed
ignore word list, see Supplementary Information). The program
was applied to the dataset using the following parameters
available in the graphical interface: Cloud Size = 100, Min
Grams = 2, Max Grams = 5, Top Journals = 10, Long Gram
Weight = ON, Remove incomplete author names = ON, and
Remove Isolated Numbers = ON.
The size of each resulting word cloud item represents the
magnitude of its n-gram’s score, taking into account the top
100 of the remaining entries. The size of each word cloud item
represents the number of publications that the corresponding
author name was found in the authors-key of the fetched
publication datasets.
A bar chart was generated to depict the number of
publications per year of the analyzed publication dataset. Another
visualization was generated to show the distribution of the
selected publications per journal. Only the top 10 journals
1https://www.nltk.org/index.html
based on the number of publications within the current dataset
were considered.
Manual Assessment of Publications
The following study characteristics were extracted from each
publication: model species, number of animals, defect site/s,
defect size and type, fixation method, inclusion and type of
cells, inclusion and type of a scaffold/construct, vector, nature of
therapy (i.e., in vivo or ex vivo), therapeutic gene/s, promoter of
therapeutic gene/s, therapy dose (including carrier information,
cell number, and modification efficiency, if available), therapy
delivery site, time between creation of defect and administration
of therapy, length of experiment, methods used to investigate
bone regeneration, and the methods used to investigate immune
response to, persistence of, and localization of gene therapy.
A RoB assessment was performed using the Systematic Review
Centre for Laboratory animal Experimentation (SYRCLE) RoB
tool for animal studies (Hooijmans et al., 2014). The tool is
a modified version of the Cochrane group RoB tool, initially
developed to standardize assessment of study biases in clinical
randomized controlled trials (RCTs). The SYRCLE RoB tool has
been modified to account for differences between clinical RCTs
and preclinical animal experiments. Briefly, the tool provides a
framework to assess if the study took adequate steps to avoid
bias through randomization and investigator blinding at various
stages, and other factors such as full data reporting. Relevant
animal baseline characteristics were decided to be age and weight.
All publications were assessed independently by two reviewers
(PW and TB) for both extracted study characteristics and the
SYRCLE RoB tool. Results were then compared and discussed,
with the consensus view presented here.
RESULTS
Data Overview (Automated Analysis)
Automated machine reading data analysis of all 33 publication
abstracts of the manuscripts selected for systematic review
illustrates that the most common converging topic areas are
centered around the use of bone marrow stromal cells (BMSCs)
and BMP genes (Figure 4A). Furthermore, there is an indication
of the relatively common use of adenoviral vectors for human
BMP (hBMP) gene delivery in several studies. The author word
cloud (Figure 4B) illustrates the most prolific authors found
in the dataset but is not a representation of overall publication
activity or leadership in the gene therapy field, as it might
represent a skewed dataset in this regard due to the performed
preselection. It gives, however, a suitable overview of the most
active authors investigating orthopedic gene therapeutics in
large animal models. Finally, publication activity in this field
peaked around 2009 (Figure 4C) in the current dataset with a
current stagnation since 2013, indicating a potential need for
more intense preclinical research activity in this field in order
to accelerate the translation of gene therapies for orthopedic
indications. The most common journals identified in the current
dataset (Figure 4D) are Gene Therapy, the Journal of Orthopaedic
Research, and Biomaterials.
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FIGURE 4 | Automated machine reading analysis of the systematic review manuscript dataset (33 publications). (A) Word cloud depicting frequency of different
n-grams across the abstracts of all selected publications. (B) Author name word cloud depicting the most common authors appearing on the highest frequency of
publications within the analyzed dataset. (C) Overview of the yearly distribution of publication numbers within the dataset. (D) List of the top 10 journals with the
most publications in the topic area within the analyzed dataset.
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Species and Models
Thirty-three publications were identified as relevant during the
search. These publications were found to have used five different
species. Dogs were used by eight publications (Bonadio et al.,
1999; Zhang et al., 2007, 2009; Xiao et al., 2010; Castro-Govea
et al., 2012; Deng et al., 2014; Liu et al., 2016; Kim et al., 2018),
goats by five publications (Dai et al., 2005; Xu et al., 2005; Lian
et al., 2009; Wegman et al., 2012; Loozen et al., 2015), sheep
by three publications (Egermann et al., 2006a,b; Santoni et al.,
2008), pigs by four publications (Park et al., 2007; Lutz et al.,
2008; Wehrhan et al., 2012, 2013), mini-pigs by eight publications
(Chang et al., 2003a,b, 2009, 2010; Chen et al., 2010; Kroczek
et al., 2010; Lin et al., 2015; Bez et al., 2017), and horses by five
publications (Backstrom et al., 2004; Ishihara et al., 2008, 2009,
2010; Southwood et al., 2012) (see Figure 5).
A wide variety of defect sites were investigated. Eight
publications created defects in the maxillofacial region (not
including the frontal bone). The specific sites investigated were
the mandible (Zhang et al., 2007, 2009; Kroczek et al., 2010;
Castro-Govea et al., 2012), inner orbit (Xiao et al., 2010; Deng
et al., 2014), sinus (Liu et al., 2016), and infraorbital rim of
the maxilla (Chang et al., 2003a). Seven publications created
defects in the cranial or calvarial region (including the frontal
bone) (Chang et al., 2003b, 2009, 2010; Park et al., 2007; Lutz
et al., 2008; Wehrhan et al., 2012, 2013). Eleven publications
created defects in the long bones of the limbs. The bones
investigated were the tibia (Bonadio et al., 1999; Dai et al., 2005;
Xu et al., 2005; Egermann et al., 2006a,b; Santoni et al., 2008;
Bez et al., 2017), femur (Bonadio et al., 1999; Lian et al., 2009;
Lin et al., 2015), ulna (Chen et al., 2010), and radius (Kim
et al., 2018). Eight publications used a handful of other sites.
These were the iliac crest (Egermann et al., 2006b; Ishihara et al.,
2010; Loozen et al., 2015), various metacarpals and metatarsals
(Backstrom et al., 2004; Ishihara et al., 2008; Ishihara et al.,
2009; Southwood et al., 2012), ribs (Ishihara et al., 2010), and L1
vertebra (Wegman et al., 2012). Various different types of defect
FIGURE 5 | Summary of the species used in the reviewed publications.
were created. Full-thickness osteotomies of long bones were made
by 14 publications (Bonadio et al., 1999; Dai et al., 2005; Xu et al.,
2005; Egermann et al., 2006a,b; Ishihara et al., 2008, 2009; Santoni
et al., 2008; Lian et al., 2009; Chen et al., 2010; Southwood et al.,
2012; Lin et al., 2015; Bez et al., 2017; Kim et al., 2018), with defect
sizes ranging from 1 to 50 mm (see Figure 6). Drill holes were
used by 11 publications (Bonadio et al., 1999; Backstrom et al.,
2004; Egermann et al., 2006b; Park et al., 2007; Lutz et al., 2008;
Chang et al., 2009; Ishihara et al., 2010; Wehrhan et al., 2012,
2013; Loozen et al., 2015). Cuboid and oval defects were used
by six publications (Chang et al., 2003a,b, 2010; Lian et al., 2009;
Zhang et al., 2009; Liu et al., 2016). A full-thickness osteotomy
followed by distraction osteogenesis was used by two publications
(Kroczek et al., 2010; Castro-Govea et al., 2012). One publication
employed a decortication approach (Wegman et al., 2012).
In long-bone studies where fixation was potentially necessary,
six used internal fixation methods; five used plates (Santoni et al.,
2008; Southwood et al., 2012; Lin et al., 2015; Bez et al., 2017;
Kim et al., 2018); one used intramedullary rods (Lian et al., 2009);
and five used external approaches, with two using plates (Bonadio
et al., 1999; Egermann et al., 2006a), two using circular/Ilizarov
frames (Dai et al., 2005; Xu et al., 2005), and one using a custom
approach (Egermann et al., 2006b). Three studies in long bones
did not state if they used fixation; however, these studies all used
sites where stability could be provided by other nearby bones
(Ishihara et al., 2008, 2009; Chen et al., 2010).
All publications delivered their gene therapy directly into the
defect. There was little variability in the length of time between
the creation of the defect and the application of gene therapy. The
large majority of publications applied their therapy immediately
after defect creation, but five left several days between defect
creation and therapy application. No chronic models were used.
One publication applied their therapy 5 days post defect creation
(Kroczek et al., 2010), while four applied their therapies 14 days
post defect creation (Ishihara et al., 2008, 2009, 2010; Bez et al.,
2017). The length of experiments (measured as the number of
days between defect creation and sacrifice of the last experimental
group) varied substantially, ranging from 28 (Park et al., 2007;
Lutz et al., 2008) to 182 days (Dai et al., 2005) (Mean 93.2,
SD 40.7; see Figure 7). The full results for species and model
information are presented in Table 2.
Scaffolds and Biomaterials
Twenty-five publications used some form of scaffold or construct
to fill the defect they had created, with a wide variety of scaffolds
being employed (Figure 8) (Bonadio et al., 1999; Chang et al.,
2003a,b, 2009, 2010; Backstrom et al., 2004; Dai et al., 2005; Park
et al., 2007; Zhang et al., 2007, 2009; Lutz et al., 2008; Santoni
et al., 2008; Lian et al., 2009; Chen et al., 2010; Xiao et al., 2010;
Castro-Govea et al., 2012; Wegman et al., 2012; Wehrhan et al.,
2012, 2013; Deng et al., 2014; Lin et al., 2015; Loozen et al.,
2015; Liu et al., 2016; Bez et al., 2017; Kim et al., 2018). Ten
publications used scaffolds that contained multiple substances
or were multiphasic (Chang et al., 2003a, 2009; Dai et al.,
2005; Zhang et al., 2007, 2009; Wegman et al., 2012; Wehrhan
et al., 2012, 2013; Loozen et al., 2015; Kim et al., 2018).
Seven publications used scaffolds that were entirely composed
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FIGURE 6 | Stacked histogram and data table of defect sizes and species for publications that used full-thickness osteotomy defects in long bones. Note that
publications that used multiple different defect sizes are included in all appropriate brackets and are counted twice if they used two different defect sizes that fell
within the same bracket. See Table 3 for full details.
FIGURE 7 | Histogram of experimental lengths for gene therapy groups across the publication set. Note that publications where experimental lengths were not clear
or where different gene therapy treatment groups were sacrificed at different times are not included in this figure. Note for binning that experiments that landed on bin
boundaries are included in the smaller bin (e.g., a 28-day experiment would be included in the 0- to 4-week bin). See Table 5 for full details.
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Defect site/s Defect size (mm; where
appropriate width × depth)
Fixation method
Backstrom et al., 2004 Horse 8 Metacarpal 3 (diaphysis and
osteochondral)
6.5 × ? Drill hole NA
Bez et al., 2017 Mini-pig (Yucatán) 18(?) Tibia 10 full-thickness osteotomies Internal, plate
Bonadio et al., 1999 Dog (mongrel) Not stated Femur, tibia 8 × 8 drill hole or 20,16,10 full
width
External, plate
Castro-Govea et al., 2012 Dog (mongrel) 9 Mandible Distraction osteogenesis:
1 mm/day for 10 days
Distraction device
Chang et al., 2003a Mini-pig (Mitsae) 20 Maxilla (infraorbital rim) 30 × 12 rectangular (full
thickness)
NA
Chang et al., 2010 Mini-pig (Mitsae) 40 Cranium (bilateral, bone
unspecified)
20 × 50 oval (full thickness) NA
Chang et al., 2003b Mini-pig (Mitsae) 20 Cranium (bilateral, bone
unspecified)
20 × 50 oval (full thickness) NA
Chang et al., 2009 Mini-pig (Mitsae) 22 “Skull” (bone unspecified) 40 × unspecified (full thickness)
drill hole
NA
Chen et al., 2010 Mini-pig (Guizhou) 18 Ulna 15 (?) None stated
(none?)
Dai et al., 2005 Goat (?) 26 Tibia 26 full-thickness osteotomies External, circular
Deng et al., 2014 Dog (beagle) 18 Orbit (bilateral, various bones) 12 × unspecified (full thickness) NA
Egermann et al., 2006a Sheep (white mountain) 12 Tibia 3 full-thickness osteotomies External, plate
Egermann et al., 2006b Sheep (white mountain) 28 Iliac crest, tibia Iliac crest: 20 × 5 drill hole;
tibia: 3
External, custom
Ishihara et al., 2008 Horse 12 Fourth metatarsal, second
metatarsal
Mt4: 1, Mt2: 10 Not stated (none?)
Ishihara et al., 2009 Horse 6 Fourth metacarpal and
metatarsal
1 full-thickness osteotomy Not stated (none?)
Ishihara et al., 2010 Horse 6 Ribs 10 or 11 (3 defects/rib, 6
defects/animal), ilium (4
defects/animal)
8 × 10 drill holes NA
Kim et al., 2018 Dog (beagle) 12 Radius 15 full-thickness osteotomies Internal, plate
Kroczek et al., 2010 Mini-pig (Göttingen) 24 Mandible Distraction osteogenesis:
1.5 mm/day for 10 days
Distraction device
Lin et al., 2015 Mini-pig (Lee-Sung) 9 Femur 30 full-thickness osteotomies Internal, plate
Liu et al., 2016 Dog (beagle) 6 Sinus (bilateral) 10 × 15 rectangular (full
thickness)
NA
Loozen et al., 2015 Goat (breed?) 10 Iliac crest (bilateral, 2 per side) 6.4 × 10 drill hole NA
Lutz et al., 2008 Pig (?) 8 Calvarium (bone unspecified, 9
defects per animal)
10 × 7 drill holes NA
Park et al., 2007 Pig (?) 8 Frontal bone (9 defects/animal) 10 × 7 drill holes NA
Santoni et al., 2008 Sheep
(Rambouillet × Columbia)
24 Tibia 50 full-thickness osteotomies Internal, plate
Southwood et al., 2012 Horse 15 Metacarpal 4 (bilateral) 15 full-thickness osteotomies Internal, plate
Wegman et al., 2012 Goat (Dutch milk) 4 L1 vertebra or muscle pockets
adjacent to spine
Unspecified size decortication Other?
Wehrhan et al., 2013 Pig (?) 20 “Frontal skull” (9 defects/animal) 10 × 10 drill hole NA
Wehrhan et al., 2012 Pig (?) 15 Calvarium (bone unspecified, 9
defect/animal)
10 × 10 drill hole NA
Xiao et al., 2010 Dog (beagle) 16 Orbit (bilateral, various bones) 12 × unspecified (full thickness) NA
Xu et al., 2005 Goat (?) 19 Tibia 21 full-thickness osteotomies External, round
Zhang et al., 2009 Dog (mongrel) 6 Mandible 6 × 4 × 5 cuboid defect NA
Zhang et al., 2007 Dog (mongrel) 9 Mandible 6 × 4 × 5 cuboid defect NA
Lian et al., 2009 Goat 20 Femur 25 full-thickness osteotomies Internal,
intramedullary rod
Question marks indicate where authors did not clearly provide the following information: species—animal breed; total number of animals—total number of animals is not
clearly stated, and therefore, values are estimates from provided group sizes; defect size—one or more dimensions of the defect were not clearly provided.
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FIGURE 8 | Set diagram representing the various biomaterials used by the
publications. Here, only publications that used a single biomaterial or a
combination of two are displayed. Two publications that used more
complicated scaffolds/constructs made up of three or more materials are not
included here. Note that publications were counted multiple times if they used
multiple different experimental groups with different biomaterials. Publications
included in the “None” group never used a biomaterial; it does not include
publications that used a biomaterial but included a no-biomaterial group. See
Table 4 for full details.
of collagen (Bonadio et al., 1999; Chang et al., 2003b, 2010;
Backstrom et al., 2004; Park et al., 2007; Lutz et al., 2008; Bez et al.,
2017), and four publications used scaffolds that contained it in
combination with other materials (Chang et al., 2003a; Dai et al.,
2005; Zhang et al., 2007, 2009). One publication used tricalcium
phosphate (TCP) alone (Deng et al., 2014), and five used some
form of calcium phosphate in combination with other materials
(Wegman et al., 2012; Wehrhan et al., 2012, 2013; Loozen et al.,
2015; Kim et al., 2018). Two publications used a scaffold solely
composed of treated bone matrix (Castro-Govea et al., 2012; Liu
et al., 2016), and three used bone matrix in combination with
other materials (Dai et al., 2005; Chen et al., 2010; Kim et al.,
2018). Two publications employed coral scaffolds (Lian et al.,
2009; Xiao et al., 2010), and none used coral in combination with
another material. Alginate was used by three publications, two
investigated alginate only scaffolds (Chang et al., 2010; Wegman
et al., 2012), and two investigated it in combination with other
materials (Wegman et al., 2012; Loozen et al., 2015) (note that
Wegman et al., 2012 tried both). Chitosan was employed by two
publications, both times in combination with collagen (Zhang
et al., 2007, 2009). One publication used gelatin in combination
with various other materials in a complex multiphasic scaffold
(Chang et al., 2009). A variety of biodegradable polymers were
used by a small number of publications, largely in combination
with other materials. Poly(ε-caprolactone) (PCL) (Kim et al.,
2018), poly(L-lactide acid) (PLLA) (Chang et al., 2003a), and
poly(ethylene glycol) (PEG) (Wehrhan et al., 2012, 2013) were
used with other materials, while one publication used poly(lactic-
co-glycolic acid) (PLGA)-only scaffold (Lin et al., 2015). Two
studies used autologous bone grafts (Park et al., 2007; Lutz et al.,
2008). Eight publications did not use a scaffold or construct (Xu
et al., 2005; Egermann et al., 2006a,b; Ishihara et al., 2008, 2009,
2010; Kroczek et al., 2010; Southwood et al., 2012). See Table 3
for full details.
Vector Systems, Therapeutic Genes,
Treatment Approaches, and Dosing
The vector systems used were less variable (see Figure 9).
Approximately two thirds of the publications used viral vectors,
accounting for 21 of the 33 publications in the set. Eighteen
publications used adenovirus, with 12 clearly indicating that they
used serotype 5 (Chang et al., 2003a,b, 2009, 2010; Dai et al.,
2005; Xu et al., 2005; Egermann et al., 2006a,b; Ishihara et al.,
2008, 2010; Castro-Govea et al., 2012; Southwood et al., 2012).
The remaining six did not clearly state which form of adenovirus
they used (Zhang et al., 2007, 2009; Ishihara et al., 2009; Lian
et al., 2009; Xiao et al., 2010; Deng et al., 2014). Two publications
used lentivirus (Liu et al., 2016; Kim et al., 2018), and a single
publication used baculovirus (Lin et al., 2015). The remaining 12
publications used non-viral gene delivery methods. Seven used
“naked” plasmids (Bonadio et al., 1999; Backstrom et al., 2004;
Chen et al., 2010; Wegman et al., 2012; Wehrhan et al., 2012, 2013;
Loozen et al., 2015), and five used plasmids with some form of
carrier (Park et al., 2007; Lutz et al., 2008; Santoni et al., 2008;
Kroczek et al., 2010; Bez et al., 2017). Eighteen publications used
ex vivo approaches (Chang et al., 2003a,b, 2009, 2010; Dai et al.,
2005; Xu et al., 2005; Ishihara et al., 2009, 2010; Lian et al., 2009;
Chen et al., 2010; Xiao et al., 2010; Castro-Govea et al., 2012;
Wehrhan et al., 2012, 2013; Deng et al., 2014; Lin et al., 2015;
Liu et al., 2016; Kim et al., 2018), 14 used in vivo approaches
(Bonadio et al., 1999; Backstrom et al., 2004; Egermann et al.,
2006a,b; Park et al., 2007; Zhang et al., 2007, 2009; Ishihara et al.,
2008; Lutz et al., 2008; Santoni et al., 2008; Kroczek et al., 2010;
Southwood et al., 2012; Loozen et al., 2015; Bez et al., 2017), and
one used a hybrid approach, where cells were sometimes included
in a gene-activated scaffold (Wegman et al., 2012). See Table 3
for full details.
Therapeutic genes were similarly consistent. Twenty-five
publications used BMP-2 (Chang et al., 2003a,b, 2009, 2010; Dai
et al., 2005; Xu et al., 2005; Egermann et al., 2006a,b; Park et al.,
2007; Ishihara et al., 2008, 2009, 2010; Lutz et al., 2008; Santoni
et al., 2008; Chen et al., 2010; Kroczek et al., 2010; Xiao et al.,
2010; Castro-Govea et al., 2012; Southwood et al., 2012; Wegman
et al., 2012; Wehrhan et al., 2012, 2013; Deng et al., 2014; Lin et al.,
2015; Loozen et al., 2015), in three cases in combination with
another gene (Chen et al., 2010; Southwood et al., 2012; Deng
et al., 2014). Of these, 19 used hBMP-2 (Chang et al., 2003a,b,
2009, 2010; Dai et al., 2005; Xu et al., 2005; Egermann et al.,
2006a,b; Park et al., 2007; Ishihara et al., 2008; Lutz et al., 2008;
Santoni et al., 2008; Chen et al., 2010; Xiao et al., 2010; Castro-
Govea et al., 2012; Southwood et al., 2012; Deng et al., 2014;
Lin et al., 2015; Loozen et al., 2015), with six not indicating the
species of origin of their gene (Ishihara et al., 2009, 2010; Kroczek
et al., 2010; Wegman et al., 2012; Wehrhan et al., 2012, 2013). Five
publications used BMP-7, with three using hBMP-7 (Zhang et al.,
2007; Lian et al., 2009; Southwood et al., 2012), one using canine
BMP-7 (Kim et al., 2018) (in a canine defect model, the only
clearly indicated case where the model species and the species of
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TABLE 3 | Study metrics 2.
Authors Cells Scaffold/construct Vector system In vivo or
ex vivo gene
therapy?
Backstrom et al., 2004 No Collagen sponge Plasmid In vivo
Bez et al., 2017 No Collagen Plasmid + microbubbles In vivo
Bonadio et al., 1999 No Collagen (mixed with the DNA) Plasmid In vivo
Castro-Govea et al., 2012 Autologous BMSCs Demineralized human bone matrix Adenovirus 5 Ex vivo
Chang et al., 2003a Autologous BMSCs PLLA + collagen Adenovirus 5 Ex vivo
Chang et al., 2010 Autologous BMSCs Alginate or collagen gel Adenovirus 5 Ex vivo
Chang et al., 2003b Autologous BMSCs Collagen Adenovirus 5 Ex vivo
Chang et al., 2009 Autologous (?) BMSCs Multiphasic: layers of pluronic F127
gel + gelatin/TCP ceramic/glutaraldehyde
composite
Adenovirus 5 Ex vivo
Chen et al., 2010 Autologous (?) ADSCs Acellular bone matrix Plasmid Ex vivo
Dai et al., 2005 Autologous BMSC Biphasic calcined bone + collagen Adenovirus 5 Ex vivo
Deng et al., 2014 Autologous BMSCs β-TCP Adenovirus (?) Ex vivo
Egermann et al., 2006a No No Adenovirus 5 In vivo
Egermann et al., 2006b No No Adenovirus 5 In vivo
Ishihara et al., 2008 No No Adenovirus 5 In vivo
Ishihara et al., 2009 Autologous fibroblasts No Adenovirus (?) Ex vivo
Ishihara et al., 2010 Autologous dermal Fbs No Adenovirus 5 Ex vivo
Kim et al., 2018 Allogeneic ADSCs PCL/β-TCP, additional demineralized bone
matrix (DBM) particles for one group
Lentivirus Ex vivo
Kroczek et al., 2010 No No Plasmid + liposome In vivo
Lin et al., 2015 Allogeneic ADSCs PLGA Baculovirus Ex vivo
Liu et al., 2016 Autologous BMSCs Bio-Oss (deproteinized bovine bone matrix) Lentivirus Ex vivo
Loozen et al., 2015 Allogeneic BMSC or
None
BCP + alginate Plasmid In vivo
Lutz et al., 2008 No Collagen or autologous bone graft Plasmid + liposome In vivo
Park et al., 2007 No Collagen sponge or autologous bone graft Plasmid + liposome In vivo
Santoni et al., 2008 No Allograft Plasmid + PLGA
microspheres
In vivo
Southwood et al., 2012 No No Adenovirus 5 In vivo
Wegman et al., 2012 Allogeneic BMSC or
none
Biphasic calcium phosphate + alginate, or
only alginate
Plasmid Hybrid
Wehrhan et al., 2013 Human fetal
osteoblasts
PEG hydrogel matrix or PEG membrane,
with HA/TCP
Plasmid Ex vivo
Wehrhan et al., 2012 Human fetal
osteoblasts
PEG hydrogel + biphasic HA/TCP Plasmid Ex vivo
Xiao et al., 2010 Autologous BMSCs Biocoral Adenovirus (?) Ex vivo
Xu et al., 2005 Autologous BMSCs No Adenovirus 5 Ex vivo
Zhang et al., 2009 No Chitosan + collagen Adenovirus (?) In vivo
Zhang et al., 2007 No Chitosan + collagen Adenovirus (?) In vivo
Lian et al., 2009 Autologous (?) BMSC Coral Adenovirus (?) Ex vivo
Question marks indicate where information was unclear. Cells—donor and recipient animals are not clearly identified, and therefore, cell status is inferred from the text;
Vector system—virus serotype not provided.
BMSC, bone marrow stromal cell; ADSC, adipose-derived mesenchymal stem cell; PLGA, poly(lactic-co-glycolic acid); PEG, poly(ethylene glycol); HA, hydroxyapatite;
TCP, tricalcium phosphate.
origin of the therapeutic gene matched) and one not indicating
the species of origin (Zhang et al., 2009). Three publications
used VEGF (Chen et al., 2010; Deng et al., 2014; Lin et al.,
2015), in all cases human. In all cases, VEGF was used either in
comparison with or simultaneously to BMP-2. Two publications
used parathyroid hormone (PTH), in both cases human and
not in combination with other genes (Bonadio et al., 1999;
Backstrom et al., 2004). BMP-6 was used by two publications
(Ishihara et al., 2008; Bez et al., 2017), in both cases human and
used in isolation, although compared with BMP-2 in one case.
Individual publications used DMP1 (Liu et al., 2016) (alone) and
PDGF-B (Zhang et al., 2009) (with or without BMP-7). In both
cases, the species of origin of the genes was not indicated. See
Table 4 for full details of the therapeutic genes used.
Promoter choice for expression cassettes was highly
consistent. Twenty-three publications used cytomegalovirus
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FIGURE 9 | Summary of the popularity of different gene transfer approaches in preclinical studies. See Table 5 for full details.
(CMV) promoter or variants such as immediate-early (CMV-IE)
(Bonadio et al., 1999; Chang et al., 2003a,b, 2009, 2010; Dai
et al., 2005; Xu et al., 2005; Egermann et al., 2006a,b; Park et al.,
2007; Zhang et al., 2007; Ishihara et al., 2008, 2010; Lutz et al.,
2008; Kroczek et al., 2010; Castro-Govea et al., 2012; Southwood
et al., 2012; Wehrhan et al., 2012, 2013; Deng et al., 2014; Lin
et al., 2015; Loozen et al., 2015; Bez et al., 2017). One publication
used the human elongation factor-1 alpha (EF-1α) promoter
(Kim et al., 2018). Nine publications did not clearly state which
promoter was used (Backstrom et al., 2004; Santoni et al., 2008;
Ishihara et al., 2009; Lian et al., 2009; Zhang et al., 2009; Chen
et al., 2010; Xiao et al., 2010; Wegman et al., 2012; Liu et al.,
2016). See Table 4 for full details.
Twenty publications used cells as part of their therapy.
Autologous BMSCs were overwhelmingly the most popular
option, being used by 11 publications (Chang et al., 2003a,b, 2009,
2010; Dai et al., 2005; Xu et al., 2005; Lian et al., 2009; Xiao et al.,
2010; Castro-Govea et al., 2012; Deng et al., 2014; Liu et al., 2016).
Various other cell types were used by two publications each.
These were autologous fibroblasts (Ishihara et al., 2009, 2010),
allogeneic BMSCs (Wegman et al., 2012; Loozen et al., 2015),
allogeneic adipose-derived mesenchymal stem cells (ADSCs) (Lin
et al., 2015; Kim et al., 2018), and human fetal osteoblasts
(Wehrhan et al., 2012, 2013). Autologous ADSCs were used
by one publication (Chen et al., 2010). Thirteen publications
did not use cells as a part of their gene therapy (Bonadio
et al., 1999; Backstrom et al., 2004; Egermann et al., 2006a,b;
Park et al., 2007; Zhang et al., 2007, 2009; Ishihara et al.,
2008; Lutz et al., 2008; Santoni et al., 2008; Kroczek et al.,
2010; Southwood et al., 2012; Bez et al., 2017). See Table 3 for
details of the cells used by the publications. Doses were highly
variable and reported in several different and non-comparable
ways depending on several factors including vector, use of cells,
use of scaffolds/constructs, and in vivo or ex vivo application.
Frequently, scaffold-based applications (largely ex vivo) did not
provide information regarding multiplicity of infection and/or
gene transfer efficiency. Sixteen publications failed to provide one
or both of these pieces of information (Chang et al., 2003a,b,
2010; Dai et al., 2005; Zhang et al., 2007, 2009; Lian et al.,
2009; Chen et al., 2010; Xiao et al., 2010; Castro-Govea et al.,
2012; Wegman et al., 2012; Wehrhan et al., 2012, 2013; Lin
et al., 2015; Loozen et al., 2015; Kim et al., 2018). The picture
is further confused by several publications that formally used
in vivo approaches but added unmodified ex vivo cells to their
gene-activated scaffolds shortly before implantation. In some
cases, the number of cells was provided, but the quantity of vector
in the scaffold was not (Zhang et al., 2007; Zhang et al., 2009). In a
handful of cases, the number of cells applied to each scaffold was
either not measured or not clearly provided (Castro-Govea et al.,
2012; Loozen et al., 2015; Liu et al., 2016; Kim et al., 2018). Non-
viral in vivo approaches accounted for five publications. The two
publications that used naked DNA used quantities measured in
tens of milligrams (Bonadio et al., 1999; Backstrom et al., 2004),
while the three publications that used carrier agents used either
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TABLE 4 | Study metrics 3.
Authors Therapeutic
gene/s
Promoter/s Dose Delivery site Length of time to gene
therapy application after







hPTH Not stated 100 mg Defect 0 84–91 (“during
week 13”)





hPTH CMV-IE 1 to 100 mg DNA Defect 0 Various (?)
Castro-Govea
et al., 2012
hBMP-2 CMV Unknown cells/scaffold





hBMP-2 CMV 1.5 × 107 cells (MOI 50, no
transduction efficiency)
Defect 0 ∼90 (3 months)
Chang et al.,
2010
hBMP-2 CMV 5 × 107 cells/scaffold (no
MOI, no transduction
efficiency)
Defect 0 ∼90 (3 months)
Chang et al.,
2003b
hBMP-2 CMV 3 × 108 cells/defect (No
MOI or transduction
efficiency)
Defect 0 ∼90 (3 months)
Chang et al.,
2009
hBMP-2 CMV 3 × 108 cells/defect (MOI
50)





Not stated Unknown cells/scaffold (no
transfection efficiency)
Defect 0 (?) 84
Dai et al., 2005 hBMP-2 (?
Inconsistently
labeled)







CMV 1 × 107 cells/scaffold (MOI






hBMP-2 CMV 1 × 1011 particles Defect 0 56
Egermann
et al., 2006b





















Defect 14 56 (42 post
therapy)







BMP-2 (?) CMV 25 µg DNA + Liposome (?) Defect 5 (?) 43 (?)
Lin et al., 2015 hBMP-2 or hVEGF CMV 1 × 108 cells (MOI 150, no
transduction efficiency)
Defect 0 84 (?)
Liu et al., 2016 DMP1 (?) Not stated Unknown cells/scaffold
(MOI 4, 95% transduction
efficiency at day 3 post
transduction as established
by fluorescence
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TABLE 4 | Continued
Authors Therapeutic
gene/s
Promoter/s Dose Delivery site Length of time to gene
therapy application after







hBMP-2 CMV Unknown cells/scaffold (no
transfection efficiency)
Defect 0 (?) 84
Lutz et al.,
2008
hBMP-2 CMV 12 µg DNA/defect Defect 0 28
Park et al.,
2007
hBMP-2 CMV 12 µg DNA Defect 0 28
Santoni et al.,
2008
hBMP-2 Not stated 100 mg
microbubble + plasmid mix
(?)





CMV 2 × 1011 particles Defect 0 112
Wegman et al.,
2012






































hBMP-7 Not stated 5 × 107 cells (MOI 100, no
transduction efficiency)
Defect 0 Experimental: ∼150
(5 months), Control:
∼240 (8 months)
In the “Therapeutic gene/s” column, an “h” prefix to a gene name indicates the gene is of human origin. Question marks indicate where the following information was
unclear. Cells—donor and recipient animals are not clearly identified therefore cell source is inferred from the text; Vector system—virus serotype not provided; Longest
follow-up period—Length not clearly indicated in the text and therefore inferred from figures.
PTH, parathyroid hormone; BMP, bone morphogenetic protein; CMV, cytomegalovirus; CMV-IE, cytomegalovirus immediate-early; MOI, multiplicity of infection; VEGF,
vascular endothelial growth factor; GFP, green fluorescent protein.
12 µg (Park et al., 2007; Lutz et al., 2008) or 1 mg (Bez et al.,
2017). See Table 4 for dosage information. Unfortunately, it was
not possible to make accurate estimates of the dose in terms
comparable with human clinical doses (mg DNA/kg bodyweight)
due to lack of information regarding the animals used. Often,
only the range of weights of animals was provided with no
measurement of central tendency, and furthermore, authors
frequently did not provide information regarding animal breed
or variety to allow a more accurate estimation. Estimated doses
varied hugely, from 5.33 × 10−5 to 7.69 mg/kg (data available
on request). All four scaffold-free viral in vivo approaches used
roughly similar amounts of vector, between 1 × 1011 and
5× 1011 particles (Egermann et al., 2006a,b; Ishihara et al., 2008;
Southwood et al., 2012). Dosage estimates in particles/kg body
weight were calculated based on estimated animal weight. Again,
measures of central tendency were not provided by three of these
publications, so rough estimates were made from the range of
animal weights. Estimated viral doses were much more consistent
than those of non-viral approaches, ranging between ∼4.7× 108
and∼1.6× 109 particles/kg (data available on request).
Outcome Parameters and Analyses
Four families of techniques were commonly used to investigate
regenerated tissue. These were 2D radiograph, CT and µCT,
histology and biomechanical testing (see Figure 10). Two-
dimensional radiographs were used by 12 publications (Bonadio
et al., 1999; Backstrom et al., 2004; Dai et al., 2005; Xu
et al., 2005; Egermann et al., 2006b; Ishihara et al., 2008,
2009; Santoni et al., 2008; Lian et al., 2009; Chen et al., 2010;
Castro-Govea et al., 2012; Southwood et al., 2012) and not used
by 21 (Chang et al., 2003a,b, 2009, 2010; Egermann et al., 2006a;
Park et al., 2007; Zhang et al., 2007, 2009; Lutz et al., 2008;
Ishihara et al., 2010; Kroczek et al., 2010; Xiao et al., 2010;
Wegman et al., 2012; Wehrhan et al., 2012, 2013; Deng et al.,
2014; Lin et al., 2015; Loozen et al., 2015; Liu et al., 2016;
Bez et al., 2017; Kim et al., 2018). CT or µCT was used by
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FIGURE 10 | Venn diagram of the most commonly used preclinical evaluation techniques across the publication set. See Supplementary Data for full details.
16 publications (Chang et al., 2003a,b, 2009, 2010; Backstrom
et al., 2004; Dai et al., 2005; Egermann et al., 2006a,b; Ishihara
et al., 2008, 2009, 2010; Xiao et al., 2010; Deng et al., 2014;
Lin et al., 2015; Bez et al., 2017; Kim et al., 2018) and not
used by 17 (Bonadio et al., 1999; Xu et al., 2005; Park et al.,
2007; Zhang et al., 2007, 2009; Lutz et al., 2008; Santoni et al.,
2008; Lian et al., 2009; Chen et al., 2010; Kroczek et al., 2010;
Castro-Govea et al., 2012; Southwood et al., 2012; Wegman et al.,
2012; Wehrhan et al., 2012, 2013; Loozen et al., 2015; Liu et al.,
2016). Histology was used by all 33 publications. Various forms
of biomechanical testing were used by 13 publications (Chang
et al., 2003a,b, 2009, 2010; Dai et al., 2005; Xu et al., 2005;
Egermann et al., 2006a,b; Ishihara et al., 2008, 2009; Lian et al.,
2009; Lin et al., 2015; Bez et al., 2017), and not used by 20
(Bonadio et al., 1999; Backstrom et al., 2004; Park et al., 2007;
Zhang et al., 2007, 2009; Lutz et al., 2008; Santoni et al., 2008;
Chen et al., 2010; Ishihara et al., 2010; Kroczek et al., 2010; Xiao
et al., 2010; Castro-Govea et al., 2012; Southwood et al., 2012;
Wegman et al., 2012; Wehrhan et al., 2012, 2013; Deng et al.,
2014; Loozen et al., 2015; Liu et al., 2016; Kim et al., 2018).
A handful of other analysis techniques were used. These were
microradiography by four publications (Park et al., 2007; Lutz
et al., 2008; Kroczek et al., 2010; Southwood et al., 2012); calcein
staining by three publications (Zhang et al., 2007, 2009; Xiao et al.,
2010); immunohistochemistry for osteogenic markers by three
publications (Bonadio et al., 1999; Wehrhan et al., 2013; Loozen
et al., 2015); and PET/CT (Lin et al., 2015), radionuclide imaging
(Chen et al., 2010), and single-photon imaging (Chen et al.,
2010) by one publication each. The remaining 24 publications
did not employ any additional methods. Outcome parameter
information is provided in full in Supplementary Table 2.
The investigation of three additional factors was taken as
a yardstick for closeness to clinical translation. These factors
were immunological response, therapy persistence, and vector
biodistribution. Note that many publications investigated vector
persistence in vitro; however, only attempts to investigate
persistence and the other factors in vivo were included at this
stage. Eleven publications made some attempt to investigate
the immune response to their therapy (Backstrom et al., 2004;
Xu et al., 2005; Egermann et al., 2006a,b; Ishihara et al.,
2008; Chen et al., 2010; Castro-Govea et al., 2012; Southwood
et al., 2012; Wehrhan et al., 2012, 2013); however, this was
often only an assessment of histology. Twenty-two publications
made no reference to the immune response to their therapy
whatsoever. Nine publications attempted to investigate transgene
or vector persistence (Bonadio et al., 1999; Chang et al., 2003a,b;
Egermann et al., 2006a,b; Santoni et al., 2008; Ishihara et al.,
2010; Wegman et al., 2012; Bez et al., 2017), while 23 did
not. Only five publications investigated vector biodistribution
(Bonadio et al., 1999; Egermann et al., 2006a,b; Ishihara et al.,
2008; Bez et al., 2017), with the remaining 28 failing to do so.
Information regarding factors vital for translation is provided in
Supplementary Table 1.
All 33 manuscripts used histological techniques that are
expensive and difficult to perform. See Table 5 for a summary
of methods used. Histological analyses were carried out
according to different protocols; therefore, the obtained
results have to be considered to be of different reliability.
Six of the 33 publications (18%) used only H&E staining
(with an additional two using Giemsa–eosin staining),
and another two studies used only toluidine blue staining.
Multicolor techniques allowing more accurate differentiation
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TABLE 5 | List of histological procedures performed in analyzed studies.
Parameters n %
Histological examination 33 100
Morphometric examination 20 60.6
Undecalcified sections in methyl methacrylate 19 57.6
Static morphometric indicators 20 60.6
Dynamic morphometric indicators 8 24.2
Von Kossa staining 4 12
Immunohistochemical study 11 33.3
of elements in the newly formed tissues—Van Gieson
bichrome, Masson trichrome, Masson–Goldner trichrome,
and Gomori and Sanderson trichrome—were used in 13
publications (39.4%).
Morphometry and statistical analysis were performed only in
60.6% (n = 20) of studies (Backstrom et al., 2004; Dai et al.,
2005; Xu et al., 2005; Egermann et al., 2006a,b; Park et al., 2007;
Zhang et al., 2007, 2009; Ishihara et al., 2008, 2009, 2010; Lutz
et al., 2008; Santoni et al., 2008; Xiao et al., 2010; Wegman
et al., 2012; Wehrhan et al., 2012, 2013; Deng et al., 2014;
Loozen et al., 2015; Liu et al., 2016), and in five cases, it did
not assess the bone tissue but additional parameters such as
the number of blood vessels, the severity of inflammation, and
the linear sizes of bone callus. Nineteen studies (57.6%) used a
complex technique for sectioning non-decalcified bone that had
been previously placed in methyl methacrylate or its analogs,
Technovit 9100 and Osteo-Bed (Polysciences) (Backstrom et al.,
2004; Egermann et al., 2006a,b; Park et al., 2007; Zhang et al.,
2007, 2009; Ishihara et al., 2008, 2009, 2010; Lutz et al., 2008;
Santoni et al., 2008; Xiao et al., 2010; Wegman et al., 2012;
Wehrhan et al., 2012, 2013; Deng et al., 2014; Loozen et al.,
2015; Liu et al., 2016; Bez et al., 2017), but only eight of
them (24.2% of all publications) then used the methods for
assessment of dynamic indicators of bone formation [measure
mineralizing surface (MS), mineral apposition rate (MAR), and
bone formation rate (BFR)] (Backstrom et al., 2004; Zhang et al.,
2007, 2009; Santoni et al., 2008; Ishihara et al., 2009, 2010; Xiao
et al., 2010; Loozen et al., 2015), the main reason for using
this technique. Static morphometric indicators were evaluated in
all experiments where morphometry was performed, and these
included the following: the proportion of bone tissue (BT/TV);
the percentage of cartilage and connective tissue in the newly
formed tissues; the areas of remaining bone substitute; and the
length of bone tissue in direct contact with bone substitute (the
percentage of available scaffold perimeter in contact to bone) or
to a metal implant (bone-to-implant contact).
Von Kossa staining, a method commonly used to characterize
mineralization of tissues, was used in 12% of the publications
(n = 4) (Chang et al., 2003a,b, 2010; Castro-Govea et al., 2012).
It is important to note that this method cannot be used to
quantify mineralization and may mask important features of
tissue reactions due to black color on histological slides. For these
reasons, it is of limited value when assessing regeneration.
Immunohistochemical technique for detecting viral particles,
expression of the protein encoded by transgene, and markers of
cell differentiation within the newly formed tissues were used in
33.3% of all studies (n = 11) (Bonadio et al., 1999; Chang et al.,
2003a,b; Park et al., 2007; Santoni et al., 2008; Kroczek et al., 2010;
Wegman et al., 2012; Wehrhan et al., 2012, 2013; Lin et al., 2015;
Loozen et al., 2015).
SYRCLE Risk of Bias Tool for Animal
Study Assessment
The SYRCLE RoB assessment revealed that a large majority
of the publications had not considered or mentioned most
factors covered by the tool (detailed analysis available on
request). Sequence generation (that is, the assignment of animals
to groups) was only randomized by six publications, with
none of these stating which randomization method was used.
Six additional publications indicated they had randomized
treatment sites within animals or used a blocking strategy,
although again none stated which randomization method was
used. The remaining 21 publications made no indication that
randomization had been considered. Only one publication
clearly indicated that animal baseline characteristics had been
considered during group allocation. Two others stated that
they had tried to balance groups based on only a subset of
our defined baseline characteristics or additional factors. The
remaining 30 publications did not address group balance. The
assessment factors of group allocation concealment, random
animal housing, investigator blinding at the treatment stage, and
random assessment at the outcome stage were not considered
by any publications. Investigator blinding at the analysis stage
was performed by two publications for portions of their data.
No publications blinded investigators for all of their data. The
remaining 31 papers did not indicate that blinding at the data
analysis stage had been considered. Thirteen publications clearly
addressed the subject of incomplete experimental outcomes,
either stating none had occurred or listing their number and
nature. Only one publication clearly stated that there had been
incomplete outcomes during the study but did not provide the
number or nature of these events. Nineteen publications did
not mention incomplete outcomes. While it is possible none
occurred in these studies, it cannot be safely assumed. Selective
outcome reporting (not providing data that the methods section
indicates was collected, or clear gaps in the methods section)
was common, with 29 publications identified to have failed to
provide some information. The large majority of these cases
were minor, with common omissions including failing to provide
non-significant p-values or histology or radiographic images
for every time point and group. More serious failings included
not clearly indicating numbers of animals used or group sizes,
providing no radiographic images despite extensive use of the
technique and providing no histology images despite extensive
use of the technique. Only four publications were found to
have provided all expected data and information. Several other
sources of bias not directly covered by the assessment were
identified across the publication set. Fourteen publications did
not indicate that they had tested if their data were normally
distributed prior to applying a parametric statistical test. Rarer
issues included exceptionally small group sizes (n = 1 or 2)
and use of animals for simultaneous experiments not included
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in the publication. The full results of the RoB assessment are
available on request.
DISCUSSION
The publications reviewed here cover a wide range of
approaches to gene therapy for bone regeneration in
large animal models. This is both a blessing and a curse.
It is clearly beneficial to attempt different approaches to
establish which methods may be the most effective. However,
there is currently such little consistency between studies
that it is very difficult to compare effectiveness. Some
simple trends across the literature can be clearly seen, for
example, aspects of vector design, the use of orthotopic
test sites, and bone analysis methods. However, almost all
other elements of experimental design are highly variable,
including crucially model species, defect sites, and specifics of
analysis techniques.
While it is difficult to make generalizations, it seems that
species choice was primarily influenced by practicality and
researcher familiarity rather than advantages of the model system.
Defects in horses were typically small and never larger than
15 mm (Southwood et al., 2012), while defects in goats were
never smaller than 21 mm (Xu et al., 2005) despite being
a substantially smaller species. A similar situation seemed to
have occurred in choice of defect site, with little rationale
provided as to why various locations where chosen. If we
consider a model system to be a species, bone, and defect
type, no particular model was used by more than a handful of
publications. Porcine cranial or calvarial defects were the most
popular, with seven publications (Chang et al., 2003b, 2009,
2010; Park et al., 2007; Wehrhan et al., 2012, 2013); however,
even this group was split between pigs and mini-pigs, and
defect locations were not described in a consistent manner (clear
indications of where defects were created were not provided, with
the terms skull, cranium, calvarium, frontal bone, and frontal
skull all used by various publications). Frequently, publications
used a combination of species, bone, and defect type that
was unique. Similarities further break down when experimental
techniques are considered. Even within a defined model system,
publications used unique combinations of defect size, fixation
method, vector, gene/s, cells, scaffold, dose, experimental length,
data collection methods, and time points. The importance of
defect fixation should not be overlooked, as fixation method
and quality influence fracture healing (O’Sullivan et al., 1989;
Claes et al., 1999; Hak et al., 2010). This will likely influence
experimental results, and the performance of novel approaches
likely should be tested using various different fixation approaches
prior to translation. Additionally, the precise biomechanics of
each defect location are unique and highly dependent on surgical
technique. Even in areas that seem to be consistent, there
were differences that lead to difficulty in comparing results.
For example, approximately one third of publications used
2D radiographs to investigate rates of defect closure, but time
points and measurement methods varied considerably between
publications. A similar situation was seen with histology and
histomorphometry, used by all the publications in the set,
where different authors often used completely different and
often highly qualitative evaluation parameters. Furthermore,
there were additional experimental procedures that were not
reviewed (though most often not provided by the publications)
that are likely to have some influence on results. The most
important was thought to be the specifics of the surgical
methods used (e.g., treatment of the periosteum), details of
vector design other than transgene and promoter, and the
length of time between modification and implantation of cells
for ex vivo approaches. Consequently, a direct comparison
of results was not possible between the large majority of
publications in the set, and even among those that were
relatively similar, it was thought to be unproductive due to
the numerous differences in experimental design. This made it
impossible to thoroughly answer the sub-questions posed at the
start of the review.
Despite difficulties in the comparison, there is a general trend
of positive results among the set. Near universally, some form
of improvement versus control groups was seen, with only two
publications showing unambiguously negative results (Santoni
et al., 2008; Southwood et al., 2012). It is of course possible
that this could be due to positive publication bias, which has
been shown to be problematic across a wide swathe of fields
and at both investigative and editorial levels (Olson et al., 2002;
Hopewell et al., 2009; Mlinarić et al., 2017). Despite this, it seems
possible to say that at a very broad level gene therapy does seem
able to improve bone regeneration at a proof-of-concept level in
these model species. This does provide an answer to the primary
question of the review but is admittedly rather unsatisfying.
The generally positive results found by the first portion of
the review are called into question by the RoB assessment,
which found that investigators are universally doing a poor
job of avoiding bias. Of the nine core factors covered by the
assessment, no publication satisfactorily addressed more than
two, and there was no indication that many of the factors were
considered by any of the publications at all. The only two factors
considered by a substantial fraction of the set were incomplete
outcome reporting and group randomization; and even so, no
publications reported randomization methods satisfactorily. In
terms of additional factors, the most serious was thought to
be potential statistical errors. Though many publications used
parametric tests, many failed to check if such approaches were
appropriate for their data. Overall, it would seem that researchers
are either unaware of or unconcerned by the risks of bias,
which can potentially lead to erroneous positive results and
cumulatively do great harm to the progress of the field if
widespread. For example, in the field of stroke, it has been
reported that apparent substantial improvements in outcome can
be largely attributed to bias, leading to a great deal of wasted time
and resources pursuing treatments that were actually much less
effective than first thought (Macleod et al., 2009). Bias is also
likely an important factor in the present reproducibility crisis
seen throughout biological science and biomedicine (Nuzzo,
2015). Based on the results of this review, it seems that the
field of gene therapy for bone regeneration is likely suffering
from the same problems as many others. A widespread and
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concerted push to improve study design in regard to bias is
clearly required.
Technology Readiness Assessment
In terms of technology readiness and closeness to translation,
it seems that there is still some way to go. While results were
generally positive, factors vital for gene therapy translation were
routinely ignored. For the purposes of this review, the three
factors of immune response, persistence of transgene expression,
and biodistribution were taken as a yardstick for closeness to
translation. Very few publications attempted to investigate these
factors in any capacity, and those that did typically did not
perform a thorough investigation (see Supplementary Table 1).
Consequently, the reviewed approaches fit within TRL 4 (see
Table 1 and Supplementary Table 4). TRL 5 would require
in-depth safety studies, which have not been performed in
these models. At the very least, more effort needs to be taken
to fully characterize where and for how long therapies are
working and possible immune responses. Alongside these, several
additional factors should be more thoroughly investigated. While
many publications demonstrated improved rates of union when
compared with controls, the quality of the bone was highly
variable or not adequately investigated. Biomechanical and
µCT results were most useful in this regard, as they produce
quantitative and potentially more comparable data. Several
publications showed that their regenerated bone had comparable
mechanical properties to native tissue (Chang et al., 2003a,b;
Ishihara et al., 2008; Lian et al., 2009; Bez et al., 2017). Other
publications found that despite improvements compared with no
treatment controls or scaffold-only treatments, the regenerated
bone showed significantly worse properties than native tissue
(Dai et al., 2005; Xu et al., 2005; Lin et al., 2015). One publication
used these methods but failed to compare with native tissue
(Ishihara et al., 2009), while most failed to use them at all.
A further criticism is the lack of comparison with existing
and alternative treatments. Few studies investigated how gene
therapy compared with autologous bone graft or recombinant
growth factors (Park et al., 2007; Lutz et al., 2008; Kroczek et al.,
2010). Only one publication, Bez et al. (2017) demonstrated
that the tissue regenerated in their experiment had properties
comparable with those of autograft controls across a variety of
techniques including crucially mechanical testing. This is likely
the clearest demonstration of non-inferiority yet provided in the
field; however, it is currently a lone outlier. Others should follow
the example of this publication when attempting to demonstrate
the non-inferiority of their own approaches.
Recommendations for Future Preclinical
Work
To improve the comparability of research in the field and help
bring gene therapy for bone regeneration closer to translation,
we suggest that several principles of experimental design,
large animal models, and investigative approaches should be
defined and broadly adhered to by the research community.
This would help to reduce bias and allow comparisons to be
more easily drawn between different studies without restricting
investigators to particular therapeutic approaches. In the
following section, we propose potential standards in these areas.
Our recommendations here are summarized in Supplementary
Figure 1. Furthermore, as discussed by Iglesias-López et al. (2019)
and in Outlook and Current Status Regarding Clinical Studies and
Authorized Clinical Gene Therapeutics for Orthopedics section,
it is essential to clearly classify the type of drug developed and
applicable translational pathway as well as to perform early
engagement with regulatory authorities to inform translation-
enabling preclinical studies, ensuring that study design and
data procurement would either support or directly feed into
preclinical data packages required for investigational new drug
(IND)-enabling studies prior to clinical trials.
Study Design and Data Reporting
We encourage investigators to adhere to the “Animal Research:
Reporting of In Vivo Experiments” (ARRIVE) guidelines
laid out by the United Kingdom National Centre for the
replacement, refinement, and reduction of animals in research
(NC3Rs) (Kilkenny et al., 2010). Additional guidance should
be taken from the “Planning Research and Experimental
Procedures on Animals: Recommendations for Excellence”
(PREPARE) guidelines from Norecopa, Norway’s National
Consensus Platform for the advancement of the 3Rs. We would
also recommend that researchers consult the SYRCLE RoB tool to
further inform themselves of reporting expectations (Hooijmans
et al., 2014). While ARRIVE and the SYRCLE RoB tools are
not formally experimental design guides, they can both act as
useful sources of information for method and data reporting
expectations and therefore inform design considerations required
to meet them. We would also recommend investigators examine
the relevant standards from the International Organization for
Standardization (ISO) to inform themselves as to the knowledge
required before beginning the process of translating an approach.
While there are presently no ISO standards specifically focusing
on gene therapies, many from the ICS 11.100.20: “Biological
evaluation of medical devices” family are relevant to GAMs. ISO
10993-1:2018 “Evaluation and testing within a risk management
process,” ISO 10993-2:2006 “Animal welfare requirements,” ISO
10993-6:2016 “Tests for local effects after implantation,” and ISO
10993-11:2017 “Tests for systemic toxicity” all contain relevant
information. Investigators pursuing cell-based therapies should
also consult ISO 13022:2012 “Medical products containing viable
human cells—Application of risk management and requirements
for processing practices.”
To investigate non-inferiority in comparison with current
treatment approaches, we recommend that investigators always
include a group treated with the current clinical gold standard,
autologous bone graft. Investigators could also include a group
treated with a recombinant version of their transgene as an
additional positive control.
Suggested Animal Model Systems
We propose two different model systems, for load-bearing and
non-load-bearing defects.
Load bearing: Sheep, femoral mid-diaphysis full-thickness
osteotomy/segmental defect.
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Non-load bearing: Mini-pig, calvarial full-
thickness oval defect.
For load-bearing defects, we have selected the sheep femoral
defect. While it could be argued that pigs are more representative
of human bone in some regard (Reichert et al., 2009; Li et al.,
2015; Wancket, 2015), sheep are of a comparable weight and
have bones of a similar size to humans and are generally
considered easier to work with. Additionally, they are a well-
established model for long bone load-bearing defects in the
regeneration of critical bone defects using other approaches
(McGovern et al., 2018). Indeed, other investigators have already
suggested sheep for standardized testing of biomaterials in
large animals, although using a different defect location and
type (Ferguson et al., 2018). For non-load-bearing defects, we
have selected mini-pigs for a standard model species. The
similarities between pig and human bone have been previously
mentioned, and mini-pigs are easier to handle than their larger
cousins. Additionally, this review has revealed that porcine
calvarial defects are currently the most popular model system
in the field; therefore, continued use of the model presents
practical advantages.
As we have previously stated in this review, there is no
clearly superior animal model for bone regeneration research,
and as such, our recommendations here are fairly arbitrary.
We are aware of the irony of suggesting our own arbitrary
guidelines after criticizing authors for not providing adequate
justification for model choice; however, we hope that the very
act of standardization could prove highly beneficial to the field.
If these suggestions prove to be impractical, we hope they will at
least spur discussion of more appropriate standardized options.
Analysis Techniques
We recommend authors place a greater emphasis on quantitative
techniques such as biomechanical testing and µCT imaging
and reduce their reliance on qualitative and semi-quantitative
approaches such as histology and 2D radiographs. Quantitative
techniques are vital for formally demonstrating the non-
inferiority of novel approaches to the existing clinical gold
standard and would allow a more valuable comparison
of data between studies. Qualitative and semi-quantitative
methods still have value as supporting information, and
standardization of approaches would further improve their
usefulness. Histology can provide extremely useful information
that is not provided by other methods if good standards
of practice, blinding, and evaluation are maintained. Novel,
automated methods in digital histology and machine learning
approaches certainly have the potential to revolutionize this
approach and provide reliable results in the future (Aeffner
et al., 2019). Undoubtedly, these techniques provide useful
information, and we do not want to discourage investigators
from their use; however, we advise against over-reliance.
A combination of various quantitative and qualitative techniques
will provide the best picture of examined tissue, adding real
value to the study.
In summary, we would like to suggest possible standards
for improving the quality, comparability, and reproducibility of
outcome measures and procedures for future preclinical work in
the field of orthopedic gene therapy (Supplementary mindmap in
Supplementary Figure 1) in addition to the recommended use of
model systems previously suggested.
Outlook and Current Status Regarding
Clinical Studies and Authorized Clinical
Gene Therapeutics for Orthopedics
To date, gene therapy for orthopedics has seen little use
in the clinic, with only a single case of clinical translation.
While numerous clinical trials have been carried out for
osteoarthritis (Evans et al., 2018) and different types of
myodystrophies, only two clinical studies have been initiated
for bone regeneration (trial numbers NCT02293031 and
NCT03076138), both in the Russian Federation. The first
of these, for a gene-activated bone substitute based on
collagen–hydroxyapatite scaffold containing a VEGFA plasmid,
was started in November 2014. Despite the positive results,
the study was withdrawn for commercial reasons (Bozo
et al., 2016). The same group proceeded with another
clinical trial aiming to investigate another gene-activated
bone substitute based on an octacalcium phosphate scaffold
and a VEGFA plasmid. The results of this study were
reported at the TERMIS-EU Meeting in Rhodes 2019 (Bozo
et al., 2019). Twenty patients with alveolar ridge atrophy
and or mandible defects were successfully treated within
6 months, and no adverse events were observed. Approval
for clinical use of this approach in the Russian Federation
was granted in April 2019 and is now available for oral
and maxillofacial surgeons. Between these two clinical trials,
another group based in Kazan, Russia, published a clinical
case report of a successful treatment of a patient with ulnar
pseudarthrosis using the GAM based on demineralized bone
allograft and a dual cassette plasmid encoding VEGFA and BMP2
(Masgutov et al., 2017).
Gene therapy for bone regeneration is now clearly on its
way to clinical practice; however, the clinical data are currently
limited, and no human trials have been performed outside the
Russian Federation. Continued successful clinical translation of
regenerative orthopedic gene therapy products is limited by
several factors closely associated with the particular complexities
of different regulatory environments. An excellent review of
EMA and FDA frameworks for advanced therapy medicinal
products (ATMPs) has been provided by Iglesias-López et al.
(2019). This diversity in definitions, legal recommendations,
and requirements for the translation of gene therapies for
regenerative medicine applications across different regulatory
framework increases risk and cost and leads to extensive
translational timeframes for gene therapy developers in this
space. In both jurisdictions, all types of advanced therapies
discussed in this review would fall under the classification
of medicines/biological products with differences in terms
of further granularity and classification [e.g., gene therapy
medicinal product (GTMP), combined ATMP (cATMP), and
CGT products]. The extent and effect on translation of global
regulatory differences and the diversity in interpretation and
preclinical and clinical study requirements of orthopedic gene
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therapy approaches can be illustrated using the specific example
of GAM translation using a biomaterial in conjunction with
a gene therapy vector. In both EMA and FDA jurisdiction,
this approach would be considered an ATMP. GAMs, for
example, are considered to be combination products under
FDA regulations. Similarly, under EMA regulations, they
fulfill the definition of a GTMP as defined in Article
2(1) of Regulation (EC) No. 1394/2007 and a cATMP as
defined in Article 2(1) of Regulation (EC) No. 1394/2007
due to the incorporation of a scaffold. The strict regulatory
environments in the United States and EU have led to relatively
slow clinical translation pathways, although novel expedited
pathways/classifications are available for accelerated translation
(e.g., RMAT in the United States). Furthermore, differences in
terms of definitions, classification, and regulatory requirements
between EMA and FDA regulatory legislation mostly require
separate, independent clinical trials and preclinical data (e.g.,
IND submission requirements in the United States) procurement
for each jurisdiction. This is further complicated by the
oversight of clinical trials by national regulatory authorities
[e.g., Medicines and Healthcare products Regulatory Agency
(MHRA) in the United Kingdom] in individual member states
in the EU. In EMA regulatory space, a centralized procedure
for market authorization is mandatory for ATMPs. Therefore,
parallel deployment of a novel gene therapy in the global
market within the United States and EU requires significant
resources and time and cannot be expedited, as for now no
harmonized procedure is available covering both regulatory
spaces. The regulatory requirements for translation of somatic
gene therapeutics are, however, substantially different inside
the Russian Federation. The advantage for rapid, accelerated
translation of a novel gene therapeutic, in particular for
regenerative applications if developed as a combination device
with a biomaterial, is that if a material contains biologically
active components, the combination product is still defined
as a medical device. Only the biological component, in this
case the plasmid DNA for GAMs, needs to be separately
registered as a drug. The first treatment to be approved
in this way was a gene therapy drug comprising plasmid
DNA encoding VEGFA (“Neovasculgen R©,” HSCI, Russia) for
the treatment of chronic lower limb ischemia. After three
clinical trials (trial numbers NCT02369809, NCT02538705,
and NCT03068585), the drug was approved in the Russian
Federation in 2011 (Deev et al., 2017) as a gene therapy.
This approval subsequently allowed the use of the authorized
Neovasculgen R© product in the Nucleostim GAM combination
device product, which is now undergoing clinical trials
in the Russian Federation or has already completed trials
depending on the indication (NCT03076138 and NCT02293031).
This peculiarity of the Russian regulatory environment for
combination products allowed a phased approach wherein an
authorized gene therapy drug can be subsequently combined
with a biomaterial and repurposed as a GAM. Thereby, for
the new indication of orthopedic gene therapy, an accelerated
path to translation can be pursued wherein the medical device
pathway can be followed even if the resulting product is
a cATMP. This means, however, that for new approaches
that are developed, all components would need to follow
separate translational pathways (i.e., the gene therapeutic
biologic component used follows drug translation pathway
and the materials have to follow the device route). Therefore,
this can only be regarded as an advantage for accelerated
translation if there is already a separate gene therapeutic that
can be repurposed and integrated to a biomaterial for the
subsequent indication.
This example illustrates that there are still significant
worldwide differences in regulatory approaches to ATMP
translation and that orthopedic gene therapy in particular
encompasses a complex array of different approaches that
can be classed as either GTMPs/CGTs or combination
approaches with different terminologies, definitions, and
regulatory requirements. Even relatively closely aligned
regulatory frameworks such as EMA and FDA exhibit
significant differences that result in the requirement of
independent translational regulatory pathways to market
authorization if one desires to bring an orthopedic gene
therapy to the clinic for patient benefit. Ultimately, it
would be highly desirable to facilitate harmonization and
convergence (Iglesias-López et al., 2019) of different regulatory
environments dealing with ATMPs to enable accelerated
translation of these promising approaches in the future
and facilitate cross-jurisdiction accreditation of preclinical
and clinical study data. This would not only facilitate the
successful deployment of these future therapies within the
orthopedic space but also eliminate or at least ameliorate
the major bottleneck of complex regulatory requirements
and highly diverse global environments. Due to the nature
of the complex matter of ATMPs and the current trend of
global political compartmentalization and fragmentation, it
is difficult to predict whether this would be a far-fetched
possibility or an illusion; it would, however, be a clear driver
to make clinical gene therapy a more widespread routine
intervention in the future.
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